# US 2004/0082607 A1 · Fused heterocyclic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082607 A1
- Document ID: US20040082607A1
- Status: Published application
- Kind: A1
- Application number: 10/470,805
- Filed: 2003-08-01
- Published: 2004-04-29
- Earliest claimed: 2001-02-02
- Assignees: Takeda Pharmaceutical Company Limited
- Inventors: Satoru Oi; Koji Ikedou; Koji Takeuchi; Masaki Ogino; Yoshihiro Banno; Hiroyuki Tawada; Taihei Yamane
- Web page: https://patentgrep.com/patent/US20040082607A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 5/48: of the pancreatic hormones
- C07D 217/24: Oxygen atoms
- C07D 217/26: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a compound of the formula: wherein ring A is an optionally substituted 5 to 10-membered aromatic ring; R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond and the like; and L is a divalent hydrocarbon group, and a salt thereof, except 3-(aminomethyl)-2,6,7-trimethyl-4-phenyl-1(2H)-isoquinolinone, 3-(aminomethyl)-2-methyl-4-phenyl-1(2H)-isoquinolinone, 3-(aminomethyl)-6-chloro-2-methyl-4-phenyl-1(2H)-isoquinolinone and 3-(aminomethyl)-2-isopropyl-4-phenyl-1(2H)-isoquinolinone. The compound shows a superior peptidase-inhibitory activity and is useful as an agent for the prophylaxis or treatment of diabetes and the like. 1

## Claims

### Claim 1

A compound of the formula
23
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent hydrocarbon group or a salt thereof, except 3-(aminomethyl)-2,6,7-trimethyl-4-phenyl-1(2H)-isoquinolinone, 3-(aminomethyl)-2-methyl-4-phenyl-1(2H)-isoquinolinone, 3-(aminomethyl)-6-chloro-2-methyl-4-phenyl-1(2H)-isoquinolinone and 3-(aminomethyl)-2-isopropyl-4-phenyl-1(2H)-isoquinolinone.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the 5 to 10-membered aromatic ring for ring A is a benzene ring.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the ring A is a 5 to 10-membered aromatic ring optionally having 1 to 3 substituent(s) selected from
a) a halogen atom,
b) a nitro group,
c) a cyano group,
d) a C1-3 alkylenedioxy group,
e) a C1-10 alkyl group or a C2-10 alkenyl group, each optionally having 1 to 3 substituent(s) selected from a halogen atom, a hydroxy group, a carboxyl group, an alkoxycarbonyl group having 2 to 8 carbon atoms, a carbamoyl group, a cyano group, an amino group, an alkanoylamino group having 2 to 8 carbon atoms, an alkoxycarbonylamino group having 2 to 8 carbon atoms, an alkylsulfonylamino group having 1 to 8 carbon atoms,
f) an optionally substituted hydroxy group,
g) an acyl group,
h) an optionally substituted amino group,
i) an aryl group having 6 to 14 carbon atoms,
j) an optionally substituted thiol group, and
k) an optionally substituted heterocyclic group.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is an alkyl group having 1 to 10 carbon atom(s).

### Claim 5 (depends on 1)

The compound of claim 1, wherein R1 is an alkyl group having 4 to 10 carbon atoms.

### Claim 6 (depends on 1)

The compound of claim 1, wherein X is a bond or —O—.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the divalent hydrocarbon group for L is an alkylene group having 1 to 10 carbon atom(s).

### Claim 8 (depends on 1)

The compound of claim 1, wherein R2 is an optionally substituted hydrocarbon group.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R2 is an alkyl group having 1 to 10 carbon atom(s), an aryl group having 6 to 14 carbon atoms or an aralkyl group having 7 to 13 carbon atoms, each optionally having 1 to 3 substituent(s) selected from halogen atom, hydroxy group, nitro group, aminogroup, optionally halogenated alkyl group having 1 to 6 carbon atom(s), alkoxy, group having 1 to 6 carbon atom(s), aromatic heterocyclic group and cycloalkyl group having 3 to 10 carbon atoms.

### Claim 10 (depends on 1)

The compound of claim 1, which is 2-[3-(aminomethyl)-4-butoxy-2-isobutyl-1-oxo-1,2-dihydro-6-isoquinolyl]-1,3-thiazole-4-carbonitrile, 2-[3-(aminomethyl)-4-butoxy-2-isobutyl-1-oxo-1,2-dihydro-6-isoquinolyl]-1,3-thiazole-4-carboxylic acid, 2-[3-(aminomethyl)-4-butoxy-2-isobutyl-1-oxo-1,2-dihydro-6-isoquinolyl]-1,3-thiazole-4-carboxamide, ethyl 2-[3-(aminomethyl)-4-butoxy-2-isobutyl-1-oxo-1,2-dihydro-6-isoquinolyl]-1,3-thiazole-4-carboxylate, (E)-3-[3-(aminomethyl)-4-butoxy-2-isobutyl-1-oxo-1,2-dihydro-6-isoquinolyl]-2-propenamide, (E)-3-[3-(aminomethyl)-2-isobutyl-4-phenyl-1-oxo-1,2-dihydro-6-isoquinolyl]-2-propenamide, 3-(aminomethyl)-2-isobutyl-1-oxo-4-phenyl-1,2-dihydro-6-isoquinolinecarboxamide, 2-[[3-(aminomethyl)-2-isobutyl-4-phenyl-1-oxo-1,2-dihydro-6-isoquinolyl]oxy]acetamide, or a salt thereof.

### Claim 11

A crystal of 2-[3-(aminomethyl)-4-butoxy-2-isobutyl-1-oxo-1,2-dihydro-6-isoquinolyl]-1,3-thiazole-4-carbonitrile or a salt thereof.

### Claim 12

A crystal of 2-[3-(aminomethyl)-4-butoxy-2-isobutyl-1-oxo-1,2-dihydro-6-isoquinolyl]-1,3-thiazole-4-carboxamide or a salt thereof.

### Claim 13

A crystal of 2-[3-(aminomethyl)-4-butoxy-2-isobutyl-1-oxo-1,2-dihydro-6-isoquinolyl]-1,3-thiazole-4-carboxamide or a salt thereof.

### Claim 14

A crystal of ethyl 2-[3-(aminomethyl)-4-butoxy-2-isobutyl-1-oxo-1,2-dihydro-6-isoquinolyl]-1,3-thiazole-4-carboxylate or a salt thereof.

### Claim 15

A crystal of (E)-3-[3-(aminomethyl)-4-butoxy-2-isobutyl-1-oxo-1,2-dihydro-6-isoquinolyl]-2-propenamide or a salt thereof.

### Claim 16

A crystal of (E)-3-[3-(aminomethyl)-2-isobutyl-4-phenyl-1-oxo-1,2-dihydro-6-isoquinolyl]-2-propenamide or a salt thereof.

### Claim 17

A crystal of 3-(aminomethyl)-2-isobutyl-1-oxo-4-phenyl-1,2-dihydro-6-isoquinolinecarboxamide or a salt thereof.

### Claim 18

A crystal of 2-[[3-(aminomethyl)-2-isobutyl-4-phenyl-1-oxo-1,2-dihydro-6-isoquinolyl]oxy]acetamide or a salt thereof.

### Claim 19

A pharmaceutical agent containing a compound of the formula
24
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent hydrocarbon group,
or a salt thereof.

### Claim 20 (depends on 19)

A pharmaceutical agent comprising the pharmaceutical agent of claim 19 in combination with at least one member selected from an insulin preparation, an insulin sensitizer, an α-glucosidase inhibitor, a biguanide and an insulin secretagogue.

### Claim 21

An agent for prophylaxis or treatment of diabetes, which contains a compound of the formula
25
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent hydrocarbon group,
a salt thereof or a prodrug thereof.

### Claim 22

An agent for prophylaxis or treatment of diabetic complications, which contains a compound of the formula
26
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent hydrocarbon group,
a salt thereof or a prodrug thereof.

### Claim 23

An agent for prophylaxis or treatment of impaired glucose tolerance, which contains a compound of the formula
27
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent hydrocarbon group,
a salt thereof or a prodrug thereof.

### Claim 24

An agent for prophylaxis or treatment of obesity, which contains a compound of the formula
28
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent, hydrocarbon group,
a salt thereof or a prodrug thereof.

### Claim 25

A peptidase inhibitor containing a compound of the formula
29
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent hydrocarbon group,
a salt thereof or a prodrug thereof.

### Claim 26 (depends on 25)

The inhibitor of claim 25, wherein the peptidase is dipeptidyl dipeptidase IV.

### Claim 27

A method of prophylaxis or treatment of diabetes in a mammal, which method comprising administering a compound of the formula
30
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent hydrocarbon group,
a salt thereof or a prodrug thereof to the mammal.

### Claim 28

A method of prophylaxis or treatment of diabetic complications in a mammal, which method comprising administering a compound of the formula
31
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent hydrocarbon group,
a salt thereof or a prodrug thereof to the mammal.

### Claim 29

A method of prophylaxis or treatment of impaired glucose tolerance in a mammal, which method comprising administering a compound of the formula
32
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent hydrocarbon group,
a salt thereof or a prodrug thereof to the mammal.

### Claim 30

A method of prophylaxis or treatment of obesity in a mammal, which method comprising administering a compound of the formula
33
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent hydrocarbon group,
a salt thereof or a prodrug thereof to the mammal.

### Claim 31

A method of inhibiting peptidase in a mammal, which method comprising administering a compound of the formula
34
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent hydrocarbon group,
a salt thereof or a prodrug thereof to the mammal.

### Claim 32

Use of a compound of the formula
35
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent hydrocarbon group,
a salt thereof or a prodrug thereof for production of an agent for prophylaxis or treatment of diabetes.

### Claim 33

Use of a compound of the formula
36
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent hydrocarbon group,
a salt thereof or a prodrug thereof for production of an agent for prophylaxis or treatment of diabetic complications.

### Claim 34

Use of a compound of the formula
37
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent hydrocarbon group,
a salt thereof or a prodrug thereof for production of an agent for prophylaxis or treatment of impaired glucose tolerance.

### Claim 35

Use of a compound of the formula
38
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent hydrocarbon group,
a salt thereof or a prodrug thereof for production of an agent for prophylaxis or treatment of obesity.

### Claim 36

Use of a compound of the formula
39
wherein
ring A is an optionally substituted 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
L is a divalent hydrocarbon group,
a salt thereof or a prodrug thereof for production of a peptidase inhibitor.

### Claim 37

A production method of a compound of the formula
40
wherein
ring A is a 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; and
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group),
or a salt thereof, which method comprises subjecting a compound of the formula.
41
wherein the symbols are as defined above, or a salt thereof, to hydrolysis.

### Claim 38

A compound of the formula
42
wherein
ring A is a 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally substituted hydrocarbon group); and
Y is a halogen atom,
or a salt thereof.

### Claim 39

A compound of the formula
43
wherein
ring A is a 5 to 10-membered aromatic ring;
R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
X is a bond, —O—, —S—, —SO—, —SO2— or —NR3— (R3 is a hydrogen atom or an optionally, substituted hydrocarbon group); and
Y is a halogen atom,
or a salt thereof.
